FdaApplication
NDA 022387
Identifiers
- fda_app_no: NDA022387
Properties
| Property | Value |
|---|---|
| applicant_name | UNITED THERAPEUTICS CORP |
| application_type | NDA |
| approval_date | 2009-07-30 |
Revenue by product
TYVASO
| Period | Revenue |
|---|---|
| Q2 2026 | $126.0M |
| Q1 2026 | $127.2M |
| Q4 2025 | $125.7M |
| Q3 2025 | $141.8M |
| Q2 2025 | $154.4M |
| Q1 2025 | $163.8M |
| Q4 2024 | $142.7M |
| Q3 2024 | $159.2M |
| Q2 2024 | $139.9M |
| Q1 2024 | $145.0M |
| Q4 2023 | $136.9M |
| Q3 2023 | $120.7M |
| Q2 2023 | $125.3M |
| Q1 2023 | $119.7M |
| Q4 2022 | $150.1M |
| Q3 2022 | $194.6M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TYVASO | TREPROSTINIL | 0.6MG/ML | SOLUTION;INHALATION |
1 product